XKRX
214150
Market cap2.14bUSD
Jul 10, Last price
48,500.00KRW
1D
-3.19%
1Q
-10.52%
IPO
950.92%
Name
Classys Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||